AmyriAD Therapeutics
CompanyUnited States
AmyriAD Therapeutics develops one asset, in human trials (Inidascamine in cognitive impairment associated with schizophrenia). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Human trials
- 0
- Trials
- 1
- Signal
Pipeline
1Human trials, Small molecule, cognitive impairment associated with schizophrenia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Signals1